Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib Combined With Anlotinib and Chemotherapy as Neoadjuvant Therapy in EGFR-mutant Resectable NSCLC
NCT07807722Phase 2Not yet recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Hubei Cancer Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
furmonertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07807722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807722.